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812-2 Endothelial Dysfunction Predicts Cardiovascular 
Events in a Multi-Ethnic General Population (Northern 
Manhattan Study)
Cairistine N. Grahame-Clarke, Carlos J. Rodriguez, Ralph L. Sacco, Robert R. Sciacca, 
Bernadette Boden-Albala, Marco Di Tullio, Shunichi Homma, Columbia-Presbyterian 
Medical Center, New York, NY
OBJECTIVES: The goal of this study was to determine the relative risk of endothelial
dysfunction for adverse cardiovascular events in the general population. BACKGROUND:
Although endothelial dysfunction is known to be associated with risk factors for athero-
sclerosis, the prognostic significance of endothelial dysfunction in the general population
is unknown. METHODS: We studied 842 subjects in a multiethnic population in northern
Manhattan,.Subjects were 55 years or older with no previous myocardial infarction or
stroke. Flow mediated vasodilation was determined at baseline. RESULTS: 555 Hispanic,
144 African American, 122 White American, and 21 other race/ethnicity subjects were
followed for a mean of 38+-11 months. Eleven myocardial infarctions, 10 strokes and 9
vascular deaths occurred during follow-up. There was a significant increase in the risk of
cardiovascular events in those with impaired flow-mediated dilation by univariate analy-
sis; (for every 1% decrease in endothelial reactivity there was an increased risk of an
event (hazard ratio [HR]: 1.14 [95% confidence interval [CI]: 1.02 to 1.27 p=0.02). CON-
CLUSIONS: Endothelial dysfunction is associated with an increased risk of vascular
events. This is the first report that endothelial dysfunction is of prognostic value in a multi-
ethnic general population.
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812-3 Correlates of Elevated C-Reactive Protein Among 
Adults in the United States: Findings From the 1999-
2000 National Health and Nutrition Examination Survey
David Klingman, Setareh Williams, Timothy Smith, Jeonghoon Ahn, Cheryl Prasad, John 
O’Donnell, ValueMedics Research, LLC., Arlington, VA, AstraZeneca Pharmaceuticals, 
LP, Wilmington, DE
Background: Elevated C-reactive protein (CRP) is a marker of inflammation and a
strong predictor of cardiovascular (CV) morbidity and mortality; however, little is known
about its prevalence and relationships with established CV risk factors. Methods: We
examined the prevalence and correlates of elevated CRP (2.0-10.0 mg/L) among 4,444
adult respondents (age >20 years) to the 1999-2000 National Health and Nutrition Exam-
ination Survey (NHANES). Demographic and clinical characteristics were screened for
crude (unadjusted) associations with elevated CRP (χ2 p-value < 0.2). We conducted a
weighted multivariate logistic regression analysis that included gender, age group, obe-
sity (body mass index > 30 kg/m2), total cholesterol (> 240 mg/dL), fasting triglyceride (>
150 mg/dL) and blood glucose (110-125 mg/dL) levels, alcohol use, low educational
attainment (< high school), history of coronary heart disease, diabetes, hypertension, or
arthritis. All analyses were performed using SUDAAN®. Results: Overall prevalence of
elevated CRP was 47.1% (male 40.2%, female 54.1%), or 76.5 million adults out of an
estimated population of 162.3 million (299 cases [6.7%] missing; 523 cases [11.8%] > 10
mg/L, which can indicate infection or trauma). Prevalence of elevated CRP was signifi-
cantly higher among the obese (odds ratio [OR] 3.54, 95% confidence interval [CI] 2.28-
5.49), ages 55-64 (OR 1.99, 95% CI 1.07-3.71) and 65-74 (OR 2.29, 95% CI 1.21-4.34)
(relative to ages 20-34), the less educated (OR 2.06, 95% CI 1.30-3.26) (relative to high
school graduates), females (OR 1.85, 95% CI 1.24-2.74), and persons with high triglycer-
ide levels (OR 1.41, 95% CI 1.04-1.91). Ethnicity, country of birth, smoking, and family
history of heart attack or angina were not significantly associated with elevated CRP.
Conclusion: Elevated CRP is a highly prevalent condition in the US. Its correlates
appear to be similar to those for other CV precursors, but key differences, particularly
regarding gender and socioeconomic status, warrant further investigation. These fea-
tures of elevated CRP may have implications for identifying persons with high CV risk, but
who may not otherwise qualify for therapy under current guidelines.
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812-4 Serum Uric Acid and Ischemic Stroke Risk Among 
Hypertensive Patients With Left Ventricular 
Hypertrophy: The Losartan Intervention for Endpoint 
Reduction in Hypertension (LIFE) Study
Jorge R. Kizer, Aud Hoieggen, Michael H. Alderman, Sverre E. Kjeldsen, Bjorn Dahlof, 
Stevo Julius, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Krister 
Kristiansson, Ole Lederballe-Pedersen, Lars H. Lindholm, Marku S. Nieminen, Per 
Omvik, Suzanne Oparil, Hans Wedel, Jonathan M. Edelman, Steven M. Snapinn, 
Richard B. Devereux, Weill Medical College of Cornell University, New York, NY, Ullevaal 
University Hospital, Oslo, Norway
Several reports have detailed an association between serum uric acid (SUA) and cardio-
vascular events. Whether such a relationship is independent of other risk factors is uncer-
tain, however, and still less is known about the relationship between SUA and ischemic
stroke. We evaluated the prognostic significance of elevated SUA at study entry for the
incidence of ischemic stroke in LIFE. The study comprised 9193 hypertensive patients
with ECG-LVH randomized to losartan or atenolol and followed for a mean of 4.8 years.
There were 480 incident ischemic strokes. SUA treated as a continuous variable was not
related to ischemic stroke in unadjusted or adjusted analyses that included treatment,
Framingham Risk Score, degree of ECG LVH, race, body mass index, pulse pressure,
exercise, alcohol use, AFib, cardiovascular disease, renal insufficiency and albuminuria.
To investigate the relationship further, sex-specific quartiles of SUA were generated
based on the distribution in the entire cohort. The highest quartile of SUA was associated
with a significantly higher risk of ischemic stroke compared to the lowest quartile (Fig-
ure), and this relationship remained significant after multivariable adjustment for all of the
above covariates (HR 1.38; 95% CI 1.04-1.84; P=0.026). In this large hypertensive
cohort with LVH, elevated SUA was an independent risk factor for ischemic stroke. Fur-
ther studies are needed to investigate this relationship and to determine whether lower-
ing of SUA can reduce cerebrovascular risk. 
Noon
812-5 Metabolic Syndrome and Cardiovascular Risk Profile in 
Patients With Myocardial Infarction
Giacomo Levantesi, Alejandro Macchia, Aldo Pietro Maggioni, Maria Grazia Franzosi, 
Luigi Tavazzi, Gianni Tognoni, Franco Valagussa, Roberto Marchioli, The GISSI 
Prevenzione Investigators, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
Background: It has been shown that the Metabolic Syndrome (MetS) increases the risk
for cardiovascular disease and developing diabetes. Since scanty data on the role of
MetS in patients with myocardial infarction (MI) are available, we analyzed the GISSI-
Prevenzione database to evaluate the prognostic role of MetS in this clinical setting.
Methods: We selected 9109 non-diabetic patients with glycaemia <126 mg% at baseline.
For MetS diagnosis we modified the ATP III criteria using BMI >26 instead of waist cir-
cumference. Cox regression models adjusted for relevant prognostic indicators were fit-
ted.
Results: 3207 patients (35.2%) had a MetS and the results of the multivariate analysis
showed a significant increased risk of death, all events (cumulative rate of all-cause mor-
tality, non fatal myocardial infarction, and non-fatal stroke), and CV events (cumulative
rate of cardiovascular death, non fatal myocardial infarction and non-fatal stroke). Finally
MetS was associated with increased probability of onset of diabetes as well as of hospi-
talization for heart failure (CHF).Conclusion: Our data suggest that the presence of MetS
Syndrome in post-MI patients confers an increased CV risk as well as of onset of diabe-
tes
